Listen
BRIVIACT (brivaracetam), antiepileptic
NEUROLOGY - New medicinal product
Opinions on drugs -
Posted on
Jan 12 2017
Reason for request
Inclusion
No clinical benefit demonstrated by comparison with other antiepileptics in the treatment of partial onset seizures, with or without secondary generalisation, in patients aged 16 years or older
- BRIVIACT has a Marketing Authorisation as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
- Without a robust comparative study, BRIVIACT did not demonstrate clinical benefit compared with other antiepileptics.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
